We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02023346
First Posted: December 30, 2013
Last Update Posted: February 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
December 23, 2013
December 30, 2013
February 8, 2017
December 2013
December 2018   (Final data collection date for primary outcome measure)
measure prognostic awareness [ Time Frame: 2 years ]
Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.
Same as current
Complete list of historical versions of study NCT02023346 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participants will be recruited from the inpatient Neurology service. Caregivers will be recruited from either the inpatient Neurology service (if they are physically present at the hospital at the time of the patient's consent to participate) or via telephone communication (if not physically present at the time of patient consent).
Malignant Glioma
Behavioral: surveys and cognitive tests
Malignant Glioma patients
This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
Intervention: Behavioral: surveys and cognitive tests
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
95
December 2018
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patient Inclusion Criteria

  • Age greater than or equal to 18
  • Diagnosis of any WHO grade III or IV glioma
  • Admitted to the inpatient Neurology service
  • Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in English

Caregiver Inclusion Criteria

  • Age greater than or equal to 18
  • Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance.
  • The patient has himself or herself agreed to participate in this study

Exclusion Criteria:

Patient Exclusion Criteria

  • A patient will be excluded if the Glasgow Coma Scale is less than 15. The patient must be oriented to self, age, place, and year, and month.
  • Aphasia precluding comprehension and verbalization of consent to participate
  • Patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. This evaluation will take place for otherwise eligible and willing participants, and it will be performed by the NP or MD clinician who is obtaining informed consent and will be documented in the medical record.

Caregiver Exclusion Criteria

  • No eligible caregivers who can complete the brief assessment in person or via telephone will be excluded
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02023346
13-253
Not Provided
Not Provided
Not Provided
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Not Provided
Principal Investigator: Eli Diamond, MD Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
February 2017